Tepezza Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tepezza market research report is one of a series of new reports that provides tepezza market statistics, including tepezza industry global market size, regional shares, competitors with a tepezza market share, detailed tepezza market segments, market trends and opportunities, and any further data you may need to thrive in the tepezza industry. This Tepezza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to a growing aging population, expansion into new geographical markets, increasing incidence of thyroid diseases, advancements in personalized medicine, and growing adoption of biologic therapies. Major trends in the forecast period include a shift towards home-based care, development of alternative administration methods, rise in combination therapies for TED, increasing focus on precision medicine, and integration of AI in treatment planning.

The increasing incidence of thyroid diseases is expected to drive the growth of the Tepezza market in the coming years. Thyroid diseases encompass a variety of conditions that affect the thyroid gland, located in the neck. The rising incidence of these diseases can be attributed to factors such as advancements in diagnostic techniques, including high-resolution ultrasound and fine-needle aspiration, which allow for earlier detection of thyroid abnormalities. Tepezza (teprotumumab) is specifically used to treat thyroid eye disease by targeting and inhibiting the insulin-like growth factor-1 receptor (IGF-1R). This helps reduce inflammation, swelling, and proptosis around the eyes. For example, in July 2022, the National Institutes of Health reported that thyroid cancer was expected to be the 13th most commonly diagnosed cancer in the U.S. in 2022, with approximately 44,000 new cases, making up about 2.3% of all cancer diagnoses. As thyroid diseases continue to increase, the Tepezza market is expected to see significant growth.

A key development in the Tepezza market is the expansion of its regulatory approvals, which aim to increase its accessibility and effectiveness in treating thyroid eye disease (TED). Regulatory approvals are formal recognitions from health authorities that ensure a drug’s safety, efficacy, and quality for its intended medical use. For instance, in April 2023, Horizon Therapeutics announced that the FDA approved a modification to the indication for Tepezza, allowing its use in patients with TED regardless of the disease's activity or duration. This update significantly enhances access to the treatment for all eligible TED patients, as Tepezza remains the only FDA-approved drug for this condition. The approval is based on data from a Phase 4 clinical trial, which demonstrated Tepezza’s effectiveness in reducing eye bulging in patients with long-term TED. The company’s CEO, Tim Walbert, emphasized that this change will improve the timely access to treatment, which will ultimately lead to better patient outcomes.

In October 2023, Amgen Inc., a U.S.-based biotechnology company, acquired Horizon Therapeutics for $27.8 billion. This acquisition strengthens Amgen’s position in the treatment of rare and inflammatory diseases by integrating Horizon’s portfolio, which includes Tepezza for thyroid eye disease, Krystexxa for chronic gout, and Uplizna for autoimmune conditions. With this acquisition, Amgen aims to broaden its range of therapies in critical therapeutic areas and accelerate its growth in the inflammation treatment market. Horizon Therapeutics, the company behind Tepezza, is a U.S.-based pharmaceutical firm that focuses on treatments for rare and serious conditions.

The key company operating in the tepezza market is Amgen Inc.

North America was the largest region in the tepezza market in 2024. The regions covered in tepezza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tepezza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tepezza is a prescription medication containing teprotumumab-trbw, a monoclonal antibody that targets and inhibits the activity of the insulin-like growth factor-1 receptor (IGF-1R). It is used to treat thyroid eye disease (TED), a rare autoimmune disorder that affects the muscles and tissues surrounding the eyes, leading to inflammation, swelling, and vision problems.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main clinical indications for Tepezza include thyroid eye disease (TED), orbital inflammatory diseases, and inflammatory ocular conditions. TED is an autoimmune disorder characterized by inflammation of the tissues around the eyes, often associated with thyroid disorders. Tepezza can be administered intravenously or subcutaneously and is distributed through hospital pharmacies and online pharmacies. It is used by a range of patients, including adults and the elderly.

The tepezza market consists of sales of pre-filled syringes, pen devices, and lyophilized powders for reconstitution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.